← Eichor
Condition: Unresectable Breast Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Breast Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06493864Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1 · 1 location(s) · Fudan University · NCT06331169Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Phase 2 · 9 location(s) · Institut Curie · NCT07193394A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07111832First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tu
Phase 1 · 37 location(s) · Relay Therapeutics, Inc. · NCT05216432Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastati
Phase 2/Phase 3 · 109 location(s) · Hoffmann-La Roche · NCT07413939A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Phase N/A · 40 location(s) · Spanish Breast Cancer Research Group · NCT02819882Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cance
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06679036A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Trip
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06471205Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pe
Phase 1 · 7 location(s) · National Cancer Institute (NCI) · NCT05372640Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory
Phase 2 · 2 location(s) · Emory University · NCT05741164A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05470348Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unrese
Phase 1 · 4 location(s) · National Cancer Institute (NCI) · NCT05111561A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 · 195 location(s) · Merck Sharp & Dohme LLC · NCT07060807Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
Phase 2 · 1 location(s) · CSPC Megalith Biopharmaceutical Co.,Ltd. · NCT07597629Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT06081959Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06434064A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecul
Phase 1/Phase 2 · 8 location(s) · Marengo Therapeutics, Inc. · NCT06827613A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Phase N/A · 54 location(s) · Daiichi Sankyo · NCT06210776
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.